Generated by All in One SEO Pro v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# LabGenius Therapeutics

ML-driven Antibody Discovery

## Sitemaps

- [XML Sitemap](https://dev-labgenius.pantheonsite.io/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://dev-labgenius.pantheonsite.io/news/) - Explore the latest news, events, and publications from LabGenius Therapeutics. Stay informed on how AI, robotics, and synthetic biology are transforming antibody drug discovery.
- [Press release | LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes](https://dev-labgenius.pantheonsite.io/sanofi/) - ● The companies have entered into a new collaboration where LabGenius Therapeutics will apply its ML-driven antibody discovery platform (EVA™) to optimise potential therapeutic NANOBODY® proteins for multiple new targets. LONDON, United Kingdom — December 4, 2025. LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential
- [Press release | LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody](https://dev-labgenius.pantheonsite.io/press-release-lgchem/) - The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform, EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit
- [Article | Programming biology: next-gen AI firms raise billions to design better medicines](https://dev-labgenius.pantheonsite.io/article-programming-biology-next-gen-ai-firms-raise-billions-to-design-better-medicines/)
- [Article | Right On-Target: Developing Safe and Selective Multispecific T-Cell Engagers](https://dev-labgenius.pantheonsite.io/article-right-on-target-developing-safe-and-selective-multispecific-t-cell-engagers/)
- [Press release | LabGenius Therapeutics Announces Poster Presentation at the AACR Annual Meeting 2026](https://dev-labgenius.pantheonsite.io/press-release-labgenius-therapeutics-announces-poster-presentation-at-the-aacr-annual-meeting-2026/) - LONDON, United Kingdom — March 17, 2026. LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI), high-throughput experimentation and machine-learning to discover next-generation therapeutic antibodies, today announced that a scientific poster will be presented at the AACR Annual Meeting 2026, being held April 17–22, 2026, at the San Diego Convention Center, California. The
- [Publication | 3in1: an ultra-fast phage display biopanning method overcoming the biopanning bias and yielding more diverse binders](https://dev-labgenius.pantheonsite.io/publication-3in1-an-ultra-fast-phage-display-biopanning-method-overcoming-the-biopanning-bias-and-yielding-more-diverse-binders/)
- [Article | Designed by AI: the future of antibody drugs](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch-3-2-2-2-2/)
- [Article | The autonomous lab](https://dev-labgenius.pantheonsite.io/article-the-autonomous-lab/)
- [Interview | Leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimisation](https://dev-labgenius.pantheonsite.io/biotechtv/)
- [Publication | Engineering multispecific antibodies with complete killing selectivity through closed-loop integration of machine learning and high-throughput experimentation](https://dev-labgenius.pantheonsite.io/engineering-multispecific-antibodies-with-complete-killing-selectivity-through-the-closed-loop-integration-of-machine-learning-and-high-throughput-experimentation/)
- [Press release | LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025](https://dev-labgenius.pantheonsite.io/esmo-immuno-oncology-congress-2025/) - LabGenius’ presentation will debut the pre-clinical in vivo efficacy and tolerability data for their lead asset, a tumour selective bispecific T-cell engager.
- [Press release | LabGenius Therapeutics Appoints Dr. Angus Sinclair as Chief Scientific Officer](https://dev-labgenius.pantheonsite.io/press-release-labgenius-therapeutics-appoints-dr-angus-sinclair-as-chief-scientific-officer/) - With over two decades of experience in senior scientific and leadership roles across the biotechnology and pharmaceutical sectors, Dr. Sinclair will now lead LabGenius Therapeutics’ drug discovery and preclinical development activities. LONDON, United Kingdom — 29/05/25. LabGenius Therapeutics (“LabGenius”) is a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise complex therapeutic
- [Blueprint Series | This AI is Creating Cancer-Killing Molecules](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch-3-2-2-2/)
- [Article | Smart Antibodies Will Transform Our Fight Against Solid Tumours](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch-3-2-2/)
- [Podcast | ‘Show me the molecule’ – On synthetic biology and cutting through AI hype](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch-3/)
- [Press release | LabGenius Therapeutics Appoints Three Experts to its Team of Scientific Advisors](https://dev-labgenius.pantheonsite.io/press-release-labgenius-therapeutics-appoints-three-experts-to-its-team-of-scientific-advisors/) - Dr. Vivek Subbiah, a leading early phase researcher, Prof. Michael Dustin, an immunology specialist, along with renowned antibody expert, Dr. Robert Lutz, will strengthen LabGenius Therapeutics’ leadership in the discovery of complex therapeutic antibodies. LONDON, United Kingdom — 13/02/25. LabGenius Therapeutics (“LabGenius”), a drug discovery company pioneering the use of machine learning and high-throughput experimentation
- [Interview | Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch-3-2/)
- [Press release | LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark](https://dev-labgenius.pantheonsite.io/press-release-labgenius-debuts-t-cell-engager-optimisation-capability-that-yields-molecules-with-400-fold-tumour-killing-selectivity-versus-clinical-benchmark/) - Download poster LONDON, United Kingdom – 15/05/23. LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) Annual 2023 Meeting, which is being held in Boston between 15-19 May. The presentation debuted data from LabGenius’ T-cell engager (TCE)
- [Press release | LabGenius’ Research Collaboration with Sanofi Yields Positive Results](https://dev-labgenius.pantheonsite.io/labgenius-research-collaboration-with-sanofi-yields-positive-results/) - Download poster Over a multi-year collaboration, LabGenius applied its ML-driven antibody engineering platform to co-optimise NANOBODY® proteins for therapeutically valuable properties. LONDON, United Kingdom – 18/09/23. LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Single-Domain Antibodies 2023 Meeting. The presentation debuted
- [Press release | LabGenius Appoints Dr. Hannah Seitz as Chief Business Officer](https://dev-labgenius.pantheonsite.io/labgenius-appoints-dr-hannah-seitz-as-chief-business-officer/) - With over 15 years of experience, the former VP Global Business Development at Evotec will lead LabGenius’ business development activities. LONDON, United Kingdom — 09/01/25 LabGenius, a drug discovery company pioneering the use of machine learning (ML) and high-throughput experimentation to discover novel therapeutic antibodies, including those with complex multispecific designs, today announced the appointment
- [Interview | James Field describes how LabGenius is using machine intelligence to design the next generation of multispecific antibodies](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch-2/)
- [Press release | LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic](https://dev-labgenius.pantheonsite.io/labgenius-raises-35-million-led-by-m-ventures-to-further-develop-its-ml-driven-antibody-discovery-platform-and-progress-a-pipeline-of-assets-towards-the-clinic/) - Additional new investors Octopus Ventures and LG Corp joined the Series B round together with existing investors including Atomico, Kindred Capital, Lux Capital and Obvious Ventures. LabGenius will use the new funds to further develop its proprietary machine learning (ML)-driven drug discovery platform, which enables the rapid identification of powerful and unique biotherapeutics. The company
- [Podcast | LabGenius' CEO, James Field, discusses ML-enabled drug discovery with Patrick Short on the Genetics Podcast](https://dev-labgenius.pantheonsite.io/labgenius-ceo-james-field-discusses-ml-enabled-drug-discovery-with-patrick-short-on-the-genetics-podcast/)
- [Blog | Q&A with Mohammad Akhlaq, Head of Automation at LabGenius](https://dev-labgenius.pantheonsite.io/labgenius-35-million-series-b-a-personal-perspective-3/) - We caught up with Mohammed Akhlaq to learn more about how he’s been getting on in his role as a Head of Automation and to hear about where he thinks machine learning will have the biggest impact on the way we approach the discovery of novel therapeutics. At the end of 2022 we welcomed Mohammed
- [Feature | BBC News covers LabGenius and how it harnesses AI in the search for new medicines](https://dev-labgenius.pantheonsite.io/bbc-news-covers-labgenius-and-how-it-harnesses-ai-in-the-search-for-new-medicines/)
- [Podcast | T-Cell Engagers: The New Cancer Drug?](https://dev-labgenius.pantheonsite.io/t-cell-engagers-the-new-cancer-drug/) - LabGenius' CTO, Leonard Wossnig, discusses the intersection of synthetic biology, high-throughput assays, and machine learning in the quest for cancer drugs with Harry Glorikian
- [Podcast | Antibody discovery with LabGenius' James Field and Balderton's James Wise](https://dev-labgenius.pantheonsite.io/antibody-discovery-with-labgenius-james-field-and-baldertons-james-wise/)
- [Podcast | LabGenius' CEO, James Field, discusses ML-enabled drug discovery as a recent guest on the Business of Biotech podcast](https://dev-labgenius.pantheonsite.io/labgenius-ceo-james-field-discusses-ml-enabled-drug-discovery-as-a-recent-guest-on-the-business-of-biotech-podcast/)
- [Podcast | Leveraging Generative AI to Design Therapeutic Antibodies](https://dev-labgenius.pantheonsite.io/the-bio-report-leveraging-generative-ai-to-design-therapeutic-antibodies/)
- [Feature | LabGenius featured in BBC Click episode, 'Combating Cancer'](https://dev-labgenius.pantheonsite.io/bbc-click-combating-cancer/)
- [Podcast | Cutting through the AI hype in drug discovery](https://dev-labgenius.pantheonsite.io/beyond-biotech-podcast-cutting-through-the-ai-hype-in-drug-discovery/)
- [Article | UK biotech raises £35M to develop solid tumour drugs based on machine learning](https://dev-labgenius.pantheonsite.io/beyond-biotech-podcast-cutting-through-the-ai-hype-in-drug-discovery-2/)
- [Award | LabGenius recognised as one of Bloomberg's start-ups to watch](https://dev-labgenius.pantheonsite.io/labgenius-recognised-as-one-of-bloombergs-start-ups-to-watch/)
- [Report | The Life Sciences Future50](https://dev-labgenius.pantheonsite.io/pwc-the-life-sciences-future50/)
- [Article | Machine Learning Enhances Antibody Discovery: A Glimpse into LabGenius and Sanofi's Collaborative Endeavour](https://dev-labgenius.pantheonsite.io/synbiobeta-machine-learning-enhances-antibody-discovery-a-glimpse-into-labgenius-and-sanofis-collaborative-endeavour/)
- [Publication | Best practices for machine learning in antibody discovery and development](https://dev-labgenius.pantheonsite.io/best-practices-for-machine-learning-in-antibody-discovery-and-development/)
- [Article | AI is Building Highly Effective Antibodies That Humans Can’t Even Imagine](https://dev-labgenius.pantheonsite.io/wired-feature-ai-is-building-highly-effective-antibodies-that-humans-cant-even-imagine/)
- [Article | Questions Every VC Needs to Ask About Every AI Startup’s Tech Stack](https://dev-labgenius.pantheonsite.io/techcrunch-questions-every-vc-needs-to-ask-about-every-ai-startups-tech-stack/)
- [Publication | Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions](https://dev-labgenius.pantheonsite.io/review-applications-and-challenges-in-designing-vhh-based-bispecific-antibodies-leveraging-machine-learning-solutions/)
- [Blog | A personal perspective on LabGenius' £35M raise from CEO, James Field](https://dev-labgenius.pantheonsite.io/labgenius-35-million-series-b-a-personal-perspective/) - At the time, this worldview was considered by many as bordering on heretical but over the intervening period, it’s become clear that this future is all but inevitable. Over several years, the LabGenius team has built and refined EVA™ — a closed-loop ML-driven robotic system capable of generating hypotheses, testing them in the lab and then using

## Pages

- [LabGenius](https://dev-labgenius.pantheonsite.io/) - LabGenius Therapeutics is pioneering a closed-loop platform that combines AI, robotic automation, and synthetic biology to accelerate the discovery of next-generation therapeutic antibodies for solid tumours.
- [Pipeline](https://dev-labgenius.pantheonsite.io/pipeline/) - Transforming the treatment of disease with a wholly-owned pipeline of highly selective therapeutic antibodies.
- [Technology](https://dev-labgenius.pantheonsite.io/technology/) - Discover the EVA™ platform at LabGenius — a modality-agnostic discovery engine that integrates ML, high-throughput automation and functional screening to deliver high-performing antibody therapeutics in under 6 weeks.
- [Partnerships](https://dev-labgenius.pantheonsite.io/partnerships/) - Partnering on the toughest challenges in multispecific antibody discovery We collaborate with top pharmaceutical partners to unlock the full potential of complex antibody constructs across a broad range of indications.Powered by the combination of high-throughput experimentation and machine learning (ML) our EVA™ platform uncovers unique, high-performing designs that are not accessible through traditional methods —
- [Contact Us](https://dev-labgenius.pantheonsite.io/contact-us/) - Reach out to LabGenius Therapeutics at our London headquarters for partnership, investment, or media enquiries. Learn how we combine human and machine intelligence to advance antibody therapeutics.
- [Careers](https://dev-labgenius.pantheonsite.io/careers/) - We’re always looking to connect with exceptional individuals who share our commitment to our mission. If you’re ready to make an impact, learn more about who we are below and explore the current opportunities on our jobs board.
- [Terms of Use](https://dev-labgenius.pantheonsite.io/terms-of-use/) - This terms of use (together with the documents referred to in it) tell you the terms of use on which you may make use of our website (www.labgeniustx.com). Use of our site includes accessing, browsing, or registering to use our site. Please read these terms of use carefully before you start to use our site, as

## Company Values

- [#humanfirst](https://dev-labgenius.pantheonsite.io/company-value/humanfirst/)
- [#raisethebar](https://dev-labgenius.pantheonsite.io/company-value/raisethebar/)
- [#curiosityisking](https://dev-labgenius.pantheonsite.io/company-value/curiosityisking/)
- [#bettertogether](https://dev-labgenius.pantheonsite.io/company-value/bettertogether/)
- [#healthmatters](https://dev-labgenius.pantheonsite.io/company-value/healthmatters/)

## Events

- [World Bispecific Europe Summit](https://dev-labgenius.pantheonsite.io/event/world-bispecific-europe-summit/)
- [BIO International](https://dev-labgenius.pantheonsite.io/event/biologic-summit/)
- [Cell Engager Therapeutics Summit](https://dev-labgenius.pantheonsite.io/event/jpm/)

## Investor Logos

- [M ventures](https://dev-labgenius.pantheonsite.io/investor-logo/m-ventures/)
- [Atomico](https://dev-labgenius.pantheonsite.io/investor-logo/atomico/)
- [Kindred](https://dev-labgenius.pantheonsite.io/investor-logo/kindred/)
- [Lux](https://dev-labgenius.pantheonsite.io/investor-logo/lux/)
- [LG](https://dev-labgenius.pantheonsite.io/investor-logo/lg/)
- [octopus ventures](https://dev-labgenius.pantheonsite.io/investor-logo/octopus-ventures/)
- [Obvious](https://dev-labgenius.pantheonsite.io/investor-logo/obvious/)

## Pipeline Items

- [LG Chem partner](https://dev-labgenius.pantheonsite.io/pipeline-item/lg-chem-partner/)
- [ADC](https://dev-labgenius.pantheonsite.io/pipeline-item/item-4/)
- [Trispecific tce](https://dev-labgenius.pantheonsite.io/pipeline-item/item-3/)
- [LGTX-101](https://dev-labgenius.pantheonsite.io/pipeline-item/item-1/)

## Team Members

- [William Strohl](https://dev-labgenius.pantheonsite.io/team-member/prof-victor-greiff/) - William (Bill) has more than 35 years of experience in biopharmaceutical research and leadership, with a deep focus on the discovery and development of antibody therapeutics. After a successful academic career in molecular biology and microbial biosynthesis, Bill joined Merck Research Laboratories, where, over the course of his 11 year tenure, he initiated the Microbial
- [Michael Dustin](https://dev-labgenius.pantheonsite.io/team-member/michael-dustin/) - Prof. Michael Dustin is the Director of Research at The Kennedy Institute of Rheumatology and Professor of Molecular Immunology. He is a leading expert in molecular immunology whose research on the immunological synapse has transformed our understanding of immune cell activation and its direct relevance to treatment of human diseases with immunotherapies. Prof. Dustin provides
- [Vivek Subbiah](https://dev-labgenius.pantheonsite.io/team-member/vivek-subbiah/) - Dr. Vivek Subbiah is the Chief of Early Phase Drug Development at Sarah Cannon Research Institute. As a leading expert in early drug development, he has served as principal investigator in over 100 Phase I/II trials and as co-investigator in more than 200 clinical trials and is known for his leadership in several first-in-human and practice-changing
- [Robert Lutz](https://dev-labgenius.pantheonsite.io/team-member/robert-lutz/) - With over 30 years of experience, including his role as VP Translational R&D at Immunogen and CSO at Iksuda, Dr. Robert Lutz has been instrumental in the discovery and development of ADCs. While at Immunogen, Dr. Lutz led several ADC programmes, including Kadcyla (the first ADC to be approved for solid tumour indications) and Elahere.
- [Hendrik-Tobias Arkenau](https://dev-labgenius.pantheonsite.io/team-member/prof-hendrik-tobias-arkenau/) - Prof Arkenau is currently serving as Chief Medical Officer and Global Head of Drug Development at Ellipses Pharma and is a highly-respected Consultant Medical Oncologist, practising at several HCA locations alongside his honorary appointment at University College London. Prior to joining industry, Prof Arkenau was Executive Medical Director of the Sarah Cannon Research Institute where
- [Gino Van Heeke](https://dev-labgenius.pantheonsite.io/team-member/gino-van-heeke/) - As LabGenius’ former CSO, Gino now supports the company’s scientific strategy, applying his deep expertise in antibody discovery to advance both platform development and pipeline innovation. Gino has over 30 years of drug discovery and development experience, having held leadership roles in both biotech and large pharmaceutical companies, including CSO at Engitix Ltd, Senior Director
- [Angus Sinclair](https://dev-labgenius.pantheonsite.io/team-member/dr-gino-van-heeke/) - As CSO, Angus leverages his broad therapeutic experiences to drive the discovery and development of novel antibody therapeutics using LabGenius Therapeutics’ advanced ML-driven protein engineering platform, EVATM . Angus brings more than 30 years of leadership experience in the discovery and development of therapeutics, successfully advancing multiple lead assets for clinical evaluation. Angus joined LabGenius
- [Hitesh Sanganee](https://dev-labgenius.pantheonsite.io/team-member/leila-zegna-2/) - Hitesh joined Octopus Ventures as a Venture Partner to support their Biotech team from his previous position as Executive Director and Global Head of Emerging Innovations at AstraZeneca. Hitesh has spent over two decades working across all aspects of drug discovery and development. He has supported a myriad of innovations across dermatology, neuroscience, oncology and
- [Sasha Vidiborskiy](https://dev-labgenius.pantheonsite.io/team-member/sasha-vidiborskiy/) - Sasha Vidiborskiy is a Partner at Atomico based in London. He is a quantum physicist by background and specialises in enterprise software and deep tech. Before joining Atomico, Sasha was a Senior Associate at Runa Capital and ran Business Operations at Bitcalm, a 1-click backup and recovery SaaS for SMEs. Sasha started his career as
- [Christian Uhrich](https://dev-labgenius.pantheonsite.io/team-member/christian-uhrich/) - Christian Uhrich joined M Ventures in August 2019 as Head of Strategy and is currently an Investment Director in the Biotechnology team. He represents M Ventures on several portfolio company boards across Therapeutics and Life Science Tools and Technology companies. Previously, he worked at Merck as a Senior Consultant where he focused on impactful strategy
- [Oliver Sims](https://dev-labgenius.pantheonsite.io/team-member/oliver-sims/) - Oliver is an Investor Director of LabGenius representing Octopus Ventures where he specialises in early-stage Biotech investments. Oliver has a background in Biomedical Science and Biochemistry, from there he transitioned to commercialising scientific ideas within the Biotech and Pharmaceutical industry in Business/Corporate Development and Entrepreneurship. His experience spans multi-specific biologics, gene editing tools and therapies
- [Edwin Moses](https://dev-labgenius.pantheonsite.io/team-member/dr-edwin-moses/) - Edwin Moses was Chief Executive Officer of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018. He was CEO of Ablynx for more than 12 years and built it from a small R&D-focused organisation into a 500-person commercial-ready business. The company developed a broad biologics pipeline including a wholly-owned product for
- [James Field](https://dev-labgenius.pantheonsite.io/team-member/dr-james-field/) - James, who is a protein engineer by training, founded LabGenius Therapeutics during his PhD studies at Imperial College London. In pursuit of LabGenius’ mission to advance the next generation of complex therapeutic antibodies, James has raised >$75M from top-tier VCs, inked R&D partnerships with leading pharma companies and overseen the development of maturation of LabGenius’
- [James Field](https://dev-labgenius.pantheonsite.io/team-member/dr-james-field-2/)
- [Edward de Moraville](https://dev-labgenius.pantheonsite.io/team-member/edward-de-moraville/) - As VP Finance, Ed manages the finance, lab operations and IT functions at LabGenius, ensuring seamless integration of systems and processes as the company scales. Ed has over a decade of finance experience, having qualified as a chartered accountant (ACA) in London before serving as Financial Controller at a circular economy startup near Cambridge for
- [Winston Haynes](https://dev-labgenius.pantheonsite.io/team-member/dr-winston-haynes/) - Winston is the VP Computational Sciences and Engineering at LabGenius, where he leads a team of experts in data science, machine learning, and software development to expand LabGenius’ ML-driven discovery platform capabilities. He has extensive experience leading the development and application of computational tools to advance both antibody therapeutics (BigHat Biosciences) and diagnostics (Serimmune). Winston
- [Catherine Howsham](https://dev-labgenius.pantheonsite.io/team-member/mohammad-akhlaq-2/) - As VP Project and Portfolio Delivery, Catherine ensures the efficient execution of scientific work packages across both pipeline and platform projects at LabGenius. Before joining LabGenius, she held senior leadership roles at Novartis and Cancer Research UK.
- [Dan Foxler](https://dev-labgenius.pantheonsite.io/team-member/dr-dan-foxler/) - Dan Foxler is the Head of Cell Biology and Assay Development at LabGenius, where he leads the Functional Assay Team. With over a decade of experience in biologics screening and more than eight years dedicated to immunotherapy discovery, Dan applies his extensive experience to advance therapeutic innovation and discovery of next-generation biologics. After earning his
- [Lucy Shaw](https://dev-labgenius.pantheonsite.io/team-member/lucy-shaw/) - At LabGenius, Lucy is responsible for the creation, management, and implementation of internal and external communications. She has over a decade of experience in healthcare marketing and communications, previously working at Ogilvy Health, where she partnered with global pharmaceutical companies to drive brand visibility, relevance, and purpose.
- [Mohammad Akhlaq](https://dev-labgenius.pantheonsite.io/team-member/mohammad-akhlaq/) - As Head of Automation, Mohammed leads a team of automation scientists who develop precision-driven robotic and laboratory automation processes. Mohammed joined LabGenius from Charles River, where he specialized in the development and automation of complex assays. Prior to that, he spent 23 years at Novartis, refining high-throughput screening methods.
- [Hannah Seitz](https://dev-labgenius.pantheonsite.io/team-member/hannah-seitz/) - As LabGenius' CBO, Hannah leverages her expertise in business development and oncology to establish strategic partnerships with biotechnology and pharmaceutical companies seeking to enhance their discovery pipelines through LabGenius’ cutting-edge platform. Hannah joined LabGenius from Evotec, where she served as VP Global Business Development for Oncology, Immunology, and Inflammation, leading global out-licensing efforts and securing
- [Michael Mullin](https://dev-labgenius.pantheonsite.io/team-member/mohammad-akhlaq-2-2/) - As Head of Antibody Engineering, Michael oversees lead discovery and production at LabGenius. He has over 20 years of experience in protein engineering and production, previously leading the Protein Technologies group at GSK, where he established a high-throughput mammalian expression platform. Michael earned his PhD from Queen’s University, Belfast, where he studied ligand-receptor interactions using
- [Oliver Hardick](https://dev-labgenius.pantheonsite.io/team-member/dr-oliver-hardick/) - Ollie is a successful entrepreneur with core expertise in the bioprocessing field, and interest more broadly in life sciences & manufacturing technologies. Completing his Engineering Doctorate at UCL 2012, he moved into the entrepreneurial world founding Puridify, a biotech tools company, which he led as CEO through VC funding to a strong exit by GE
- [Leila Zegna](https://dev-labgenius.pantheonsite.io/team-member/leila-zegna/) - Leila is a founding partner at Kindred Capital and acts as Board Observer at LabGenius. She is both an investor and an entrepreneur, with over a decade of operating experience in technology businesses across three continents. Leila holds an MBA from Harvard Business School, as well as a BS in Mathematics and Philosophy from Yale